ArticleCancer research2022

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.

Zena Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.